ALLUVI: A DETAILED DIVE INTO THE DRUG'S PROSPECTS

Alluvi, formerly BI 4744, presents a promising development in obesity treatment. This dual stimulator targeting both glucagon-like peptide-1 and GIP sites demonstrates impressive efficacy in patient studies, arguably exceeding current GLP-1 target activators. Early data indicate substantial {weig